OakChart

Telomir Pharmaceuticals Inc

TELOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.5950+0.0229 (4.00%)
2026-11-12 05:01 CET
Market cap
43.84 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-51.59 USD m
Free cash flow, TTM
-4.57 USD m
EPS diluted, TTM
-0.89
P/E
-
Compare

Price

TELO against its 20, 50 and 200-day averages
2050200earnings
0.500.751.001.251.50627K1.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TELOclose 0.6020-day 0.9150-day 1.07200-day 1.200.6052w high52w low

62.3% under the 52-week high of 1.58 on 6 Oct 2026. 52-week low 0.55 on 10 Nov 2026. Last 15 sessions, 96.3% high to low

Volume 3.25× normal · the line is the 50-bar volume average

Profile

TELO
52-week range, 5% of the way up
0.541.58

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Employees2
IPOFeb 09, 2024
Beta0.01
ATR, 14d0.09
Rel volume3.25
Short float1.02%
Insider own0.00%
Inst own4.12%

Snapshot

6 groups

Valuation

Index-
Market Cap43.84M
Enterprise Value39.39M
Income-51.59M
Sales0.00M
Book/sh0.06
Cash/sh0.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2
IPOFeb 09, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B9.29
P/C9.70
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio19.60
Current Ratio19.60
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.89
EPS next Y-0.11
EPS next Q-0.03
EPS this Y-
EPS next Y-
EPS next 5Y32.79%
EPS past 3/5Y-125.22% -189.25%
Sales past 3/5Y- -
EPS Y/Y TTM-136.90%
Sales Y/Y TTM-
EPS Q/Q70.00%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own4.12%
Inst Trans5.63%
ROA-90.99%
ROE-96.26%
ROIC-124.39%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-34.36%
SMA50-44.14%
SMA200-50.39%
Trades-

Technical

Shs Outstand73.68M
Shs Float73.68M
Short Float1.02%
Short Ratio7.56
Short Interest0.75M
52W High1.58 -62.34%
52W Low0.54 9.18%
Volatility19.04% 10.14%
ATR (14)0.09
RSI (14)15.43
Beta0.01
Rel Volume3.25
Avg Volume99.22K
Volume322,550

Performance

Perf Week-32.00%
Perf Month-45.41%
Perf Quarter-43.33%
Perf Half Y-51.63%
Perf YTD-55.26%
Perf Year-58.10%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price6.00
Prev Close0.57
Price0.60
Change %4.00%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Feb 21, 2025InitiatedRRodman & RenshawBuy$15+2,421.0%

Peers

Mkt cap
TickerCompanyMkt cap
ANVSAnnovis Bio Inc36.41M
ATOSAtossa Therapeutics Inc20.26M
BIVIBioVie Inc13.51M
CLNNClene Inc60.40M
GANXGain Therapeutics Inc48.45M
ALZNAlzamend Neuro Inc6.32M
JUNSJupiter Neurosciences Inc2.82M
LGVNLongeveron Inc10.52M
NRSNNeuroSense Therapeutics Ltd3.38M
ENVBEnveric Biosciences Inc6.67M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 146
  • Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company (GlobeNewswire)
  • Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) (GlobeNewswire)
  • Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models (GlobeNewswire)
  • Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models (GlobeNewswire)
  • Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model (ACCESSWIRE)
  • Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease (ACCESSWIRE) +7.38%
  • Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer (ACCESSWIRE)
  • Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) (ACCESSWIRE)
  • Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma (TMX Newsfile)
  • Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer (ACCESSWIRE) +14.04%
  • Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman (TMX Newsfile)
  • Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models (ACCESSWIRE) +5.50%
  • Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging (ACCESSWIRE)
  • Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models (ACCESSWIRE) +11.19%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.030--0.7860.00--
2025Q22025-09-03-0.080-0.080-0.1690.000.001
2025Q12025-05-28-0.070-0.070-0.0730.000.001
2024Q42025-02-26-0.070-0.085-0.0980.000.002
2024Q32024-11-27-0.200-0.200-0.2020.000.001
2024Q22024-08-28-0.060--0.0490.00--
2025Q3---0.080-0.034-0.001
2025Q4---0.080-0.060-0.001
2026Q1---0.070-0.029-0.001
2026Q3---0.030---1
2026Q4---0.030---1
2027Q1---0.040---1
2027Q2---0.040---1
2027Q3---0.040---1
2027Q4---0.050---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-0.560-0.560-0.000.00
2025FY--0.310-0.329-0.00
2026FY--0.280--1.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2025-10-301000.500.500.50
2026Q3S2025-10-291000.500.500.50
2026Q3S2025-10-281000.500.500.50
2026Q3S2025-10-271000.500.500.50
2026Q3S2025-10-261000.500.500.50
2026Q3S2025-10-251000.500.500.50
2026Q3S2025-10-241000.500.500.50
2026Q3S2025-10-231000.500.500.50
2026Q3S2025-10-221000.500.500.50
2026Q3S2025-10-211000.500.500.50
2026Q3S2025-10-201000.500.500.50
2026Q3S2025-10-191000.500.500.50
2026Q3S2025-10-181000.500.500.50
2026Q3S2025-10-171000.500.500.50

Estimate history

EPS, annual-0.005-0.029-0.442-0.56-0.329-0.8853
Period20212022202320242025TTM
EPS, quarterly-0.202-0.098-0.073-0.169-0.034-0.06-0.029-0.786-0.01
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual29.6129.6129.6129.76334.38168.775
Period20212022202320242025MRQ
Shares, quarterly29.6129.76329.76330.51433.83134.38134.38168.77568.775
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
Selling, General and Administrative Excl. Other5.6910.5412.243.940.850.14
Research and Development2.462.442.241.570.830.13
Other Operating Expense0.000.000.000.000.000.00
Operating Income-5.69-10.54-12.24-3.94-0.85-0.14
Interest Expense0.010.004.341.640.000.00
Unusual Expense0.000.000.007.490.000.00
Net Income Before Taxes-5.48-10.41-16.53-13.07-0.85-0.14
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-5.48-10.41-16.53-13.07-0.85-0.14
Net Income From Continuing Operations-5.48-10.41-16.53-13.07-0.85-0.14
Net Income-51.59-10.41-16.53-13.07-0.85-0.14
EPS (Recurring)-0.75-0.33-0.56-0.26-0.03-0.00
EPS (Basic, Before Extraordinaries)-0.89-0.33-0.56-0.44-0.03-0.00
EPS (Diluted)-0.89-0.33-0.56-0.44-0.03-0.00
EBITDA-5.69-10.54-12.24-3.94-0.85-0.14
Non-Operating Income (Expense)0.210.130.050.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense-5.296.87---
Shares Outstanding68.7734.3829.7629.6129.6129.61
Market Capitalization43.8443.84122.58138.05--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other0.751.761.042.131.155.072.192.91
Research and Development0.250.440.471.300.760.040.340.27
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.75-1.76-1.04-2.13-1.15-5.07-2.19-2.91
Interest Expense0.000.000.000.000.000.00--
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-0.71-1.72-0.99-2.06-1.10-5.07-2.18-2.90
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-0.71-1.72-0.99-2.06-1.10-5.07-2.18-2.90
Net Income From Continuing Operations-0.71-1.72-0.99-2.06-1.10-5.07-2.18-2.90
Net Income-0.71-47.84-0.99-2.06-1.10-5.07-2.18-2.90
EPS (Recurring)-0.01-0.79-0.03-0.06-0.03-0.17-0.07-0.10
EPS (Basic, Before Extraordinaries)-0.01-0.79-0.03-0.06-0.03-0.17-0.07-0.10
EPS (Diluted)-0.01-0.79-0.03-0.06-0.03-0.17-0.07-0.10
EBITDA-0.75-1.76-1.04-2.13-1.15-5.07-2.19-2.91
Non-Operating Income (Expense)0.040.050.050.070.040.000.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.080.200.04-0.103.821.382.06
Shares Outstanding68.7768.7734.3834.3833.8330.5129.7629.76
Market Capitalization43.8488.0344.7045.7344.8737.2096.13122.58

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments7.291.270.000.000.00
Short Term Receivables0.000.000.130.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.050.060.000.000.00
Total Current Assets7.341.320.130.000.00
Net Property, Plant & Equipment0.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.00
Long-Term Note Receivable---0.000.06
Intangible Assets0.000.000.000.000.00
Other Assets0.000.004.640.050.00
Total Assets7.341.324.770.050.06
Short Term Debt Incl. Current Port. of LT Debt0.000.000.100.000.00
Accounts Payable0.540.590.710.400.02
Other Current Liabilities0.890.090.530.580.12
Total Current Liabilities1.430.681.340.990.14
Long Term Debt0.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities1.430.681.340.990.14
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity5.910.643.44-0.94-0.08
Total Shareholders Equity5.910.643.44-0.94-0.08
Accumulated Minority Interest0.000.000.000.000.00
Total Equity5.910.643.44-0.94-0.08
Total Liabilities & Stockholders Equity7.341.324.770.050.06
Book Value Per Share0.170.020.12-0.03-0.00
Tangible Book Value Per Share0.170.020.12-0.03-0.00
Full-Time Employees259--
Price to Book Ratio9.29275.95310.78--
Return on Assets-240.34-542.25-542.12-1,646.87-
Return on Equity-317.65-810.18-1,045.36--
Return on Invested Capital-176.10-2,571.04-380.19--
Quick Ratio5.141.940.100.000.00
Current Ratio5.141.940.100.000.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-5.48-10.41-16.53-13.07-0.85-0.14
Other Funds (Non Cash)0.896.1311.349.100.000.00
Funds from Operations-4.58-4.28-5.20-3.97-0.85-0.14
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.010.590.130.110.390.02
Cash from Operating Activities-4.57-3.69-5.07-3.86-0.47-0.12
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock2.019.556.871.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.019.556.871.000.000.00
Proceedsfrom Stock Options2.019.556.831.000.000.00
Issuance or Reduction of Debt, Net0.000.00-0.103.170.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.250.16-0.43-0.310.470.12
Other Financing Activities Uses-0.630.00-0.43-0.31-0.050.00
Cash from Financing Activities1.769.716.343.860.470.12
Net Change in Cash-2.816.021.26-0.000.000.00
Free Cash Flow-4.57-3.69-5.07-3.86-0.47-0.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments4.525.175.567.297.330.75
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.130.200.230.050.070.08
Total Current Assets4.645.375.797.347.400.83
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets4.645.375.797.347.400.83
Short Term Debt Incl. Current Port. of LT Debt0.070.140.200.000.000.00
Accounts Payable0.170.200.280.540.330.25
Other Current Liabilities0.000.000.340.890.090.09
Total Current Liabilities0.240.330.831.430.420.35
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.240.330.831.430.420.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.405.034.965.916.980.48
Total Shareholders Equity4.405.034.965.916.980.48
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.405.034.965.916.980.48
Total Liabilities & Stockholders Equity4.645.375.797.347.400.83
Book Value Per Share0.060.070.140.170.210.02
Tangible Book Value Per Share0.060.070.140.170.210.02
Full-Time Employees---2--
Price to Book Ratio9.298.877.566.4588.14-231.05
Return on Assets-90.99-189.68-293.73-240.34-266.47-1,101.13
Return on Equity-96.26-213.10-384.26-317.65-303.19-1,575.45
Return on Invested Capital-16.01-34.20-19.97-34.86-15.79-1,053.54
Quick Ratio19.6016.147.005.1417.512.38
Current Ratio19.6016.147.005.1417.512.38

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-0.71-1.72-0.99-2.06-1.10-5.07
Other Funds (Non Cash)0.080.790.04-0.010.104.66
Funds from Operations-0.63-0.94-0.95-2.07-1.00-0.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.04-0.08-0.820.870.08-0.29
Cash from Operating Activities-0.59-1.01-1.77-1.20-0.93-0.70
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock0.001.010.001.007.501.05
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.001.010.001.007.501.05
Proceedsfrom Stock Options0.001.010.001.007.501.05
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.07-0.380.050.160.000.00
Other Financing Activities Uses-0.07-0.38-0.180.000.000.00
Cash from Financing Activities-0.070.620.051.167.501.05
Net Change in Cash-0.65-0.39-1.73-0.046.570.35
Free Cash Flow-0.59-1.01-1.77-1.20-0.93-0.70

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.02%0.8M73.7M84.62K
2026-10-151.05%0.8M73.6M99.76K
2026-09-302.37%0.8M34.8M76.43K
2026-09-152.23%0.8M34.8M90.30K
2026-08-311.19%0.8M68.8M98.91K
2026-08-142.34%0.8M34.8M104.21K
2026-07-312.51%1.0M38.4M112.71K
2026-07-155.27%1.0M18.5M149.11K
2026-06-305.16%1.0M18.5M152.11K
2026-06-155.10%0.9M18.5M134.13K
2026-05-294.99%0.9M18.5M132.29K
2026-05-155.64%1.0M18.5M133.12K
2026-04-3013.22%1.0M7.7M138.38K
2026-04-156.69%1.0M15.5M103.81K
2026-03-318.85%1.2M13.9M121.05K
2026-03-139.23%1.3M13.9M151.73K
2026-02-2710.40%1.4M13.9M180.56K
2026-02-1310.98%1.5M13.9M304.88K
2026-01-309.43%1.5M15.4M361.09K
2026-01-159.57%1.5M15.4M661.42K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-05EFFECTEffectiveness filing by commission orderSEC
2026-11-05424B3SEC
2026-10-27S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-068-KCurrent report2026-10-05SEC
2026-09-178-KCurrent report2026-09-17SEC
2026-09-168-KCurrent report2026-09-11SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-19DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-28SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-07-274Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-06-093Initial statement of beneficial ownership of securities2026-06-03SEC
2026-06-088-KCurrent report2026-06-03SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-208-KCurrent report2026-05-20SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-308-KCurrent report2026-04-24SEC
2026-04-244Statement of changes in beneficial ownership of securities2026-04-22SEC
2026-04-248-KCurrent report2026-04-22SEC
2026-03-318-KCurrent report2026-03-30SEC
2026-03-318-KCurrent report2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.35%
GEODE CAPITAL MANAGEMENT, LLC0.64%
BlackRock, Inc.0.41%
VANGUARD FIDUCIARY TRUST CO0.33%
NORTHERN TRUST CORP0.09%
STATE STREET CORP0.09%
Bank of New York Mellon Corp0.07%
CAPTRUST FINANCIAL ADVISORS0.07%
OSAIC HOLDINGS, INC.0.06%
World Investment Advisors0.05%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.63%
VANGUARD EXTENDED MARKET INDEX FUND0.69%
Fidelity Extended Market Index Fund0.30%
Fidelity Series Total Market Index Fund0.07%
iShares Micro-Cap ETF0.05%
Fidelity Total Market Index Fund0.05%
VANGUARD BALANCED INDEX FUND0.03%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.00%

OakChart. TELO. Cached 15 minutes.

Some panels did not load: insider.